Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk

K Weisel; A Spencer; S Lentzsch; H Avet-Loiseau; T M Mark; I Spicka; T Masszi; B Lauri; Mark-David Levin; A Bosi; V Hungria; M Cavo; JJ Lee; A Nooka; H Quach; M Munder; C Lee; W Barreto; P Corradini; CK Min; AA Chanan-Khan; N Horvath; M Capra; M Beksac; R Ovilla; J C Jo; HJ Shin; Pieter Sonneveld; T Casneuf; N Deangelis; H Amin; J Ukropec; R Kobos; MV Mateos

doi:10.1186/s13045-020-00948-5

Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk

K Weisel, A Spencer, S Lentzsch, H Avet-Loiseau, T M Mark, I Spicka, T Masszi, B Lauri, Mark-David Levin, A Bosi, V Hungria, M Cavo, JJ Lee, A Nooka, H Quach, M Munder, C Lee, W Barreto, P Corradini, CK MinAA Chanan-Khan, N Horvath, M Capra, M Beksac, R Ovilla, J C Jo, HJ Shin, Pieter Sonneveld, T Casneuf, N Deangelis, H Amin, J Ukropec, R Kobos, MV Mateos

Hematology

Research output: Contribution to journal › Article › Academic

32 Citations (Scopus)

18 Downloads (Pure)

Original language	English
Article number	115
Journal	Journal of Hematology and Oncology
Volume	13
Issue number	1
DOIs	https://doi.org/10.1186/s13045-020-00948-5
Publication status	Published - 2020

Research programs

EMC NIHES-02-65-01

Access to Document

10.1186/s13045-020-00948-5

Repub_129801_O-A.pdfFinal published version, 883 KB

http://hdl.handle.net/1765/129801

Cite this

Weisel, K., Spencer, A., Lentzsch, S., Avet-Loiseau, H., Mark, T. M., Spicka, I., Masszi, T., Lauri, B., Levin, M.-D., Bosi, A., Hungria, V., Cavo, M., Lee, JJ., Nooka, A., Quach, H., Munder, M., Lee, C., Barreto, W., Corradini, P., ... Mateos, MV. (2020). Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk. Journal of Hematology and Oncology, 13(1), Article 115. https://doi.org/10.1186/s13045-020-00948-5

@article{4a3ae139d91b4ec7aede2cccbadac76d,

title = "Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk",

author = "K Weisel and A Spencer and S Lentzsch and H Avet-Loiseau and Mark, {T M} and I Spicka and T Masszi and B Lauri and Mark-David Levin and A Bosi and V Hungria and M Cavo and JJ Lee and A Nooka and H Quach and M Munder and C Lee and W Barreto and P Corradini and CK Min and AA Chanan-Khan and N Horvath and M Capra and M Beksac and R Ovilla and Jo, {J C} and HJ Shin and Pieter Sonneveld and T Casneuf and N Deangelis and H Amin and J Ukropec and R Kobos and MV Mateos",

year = "2020",

doi = "10.1186/s13045-020-00948-5",

language = "English",

volume = "13",

journal = "Journal of Hematology and Oncology",

issn = "1756-8722",

publisher = "BioMed Central Ltd.",

number = "1",

}

Weisel, K, Spencer, A, Lentzsch, S, Avet-Loiseau, H, Mark, TM, Spicka, I, Masszi, T, Lauri, B, Levin, M-D, Bosi, A, Hungria, V, Cavo, M, Lee, JJ, Nooka, A, Quach, H, Munder, M, Lee, C, Barreto, W, Corradini, P, Min, CK, Chanan-Khan, AA, Horvath, N, Capra, M, Beksac, M, Ovilla, R, Jo, JC, Shin, HJ, Sonneveld, P, Casneuf, T, Deangelis, N, Amin, H, Ukropec, J, Kobos, R & Mateos, MV 2020, 'Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk', Journal of Hematology and Oncology, vol. 13, no. 1, 115. https://doi.org/10.1186/s13045-020-00948-5

TY - JOUR

T1 - Daratumumab, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma: Subgroup analysis of CASTOR based on cytogenetic risk

AU - Weisel, K

AU - Spencer, A

AU - Lentzsch, S

AU - Avet-Loiseau, H

AU - Mark, T M

AU - Spicka, I

AU - Masszi, T

AU - Lauri, B

AU - Levin, Mark-David

AU - Bosi, A

AU - Hungria, V

AU - Cavo, M

AU - Lee, JJ

AU - Nooka, A

AU - Quach, H

AU - Munder, M

AU - Lee, C

AU - Barreto, W

AU - Corradini, P

AU - Min, CK

AU - Chanan-Khan, AA

AU - Horvath, N

AU - Capra, M

AU - Beksac, M

AU - Ovilla, R

AU - Jo, J C

AU - Shin, HJ

AU - Sonneveld, Pieter

AU - Casneuf, T

AU - Deangelis, N

AU - Amin, H

AU - Ukropec, J

AU - Kobos, R

AU - Mateos, MV

PY - 2020

Y1 - 2020

U2 - 10.1186/s13045-020-00948-5

DO - 10.1186/s13045-020-00948-5

M3 - Article

C2 - 32819447

SN - 1756-8722

VL - 13

JO - Journal of Hematology and Oncology

JF - Journal of Hematology and Oncology

IS - 1

M1 - 115

ER -